{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:32:36Z","timestamp":1767904356545,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"DOI":"10.1186\/s13104-025-07593-6","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:53:54Z","timestamp":1765014834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of initiating SGLT2 inhibitors on eGFR: a pilot study at a secondary hospital in Malaysia"],"prefix":"10.1186","volume":"19","author":[{"given":"Shing Shen","family":"Bay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Haziqah","family":"Baharom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah Faiz","family":"Zaihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"2","key":"7593_CR1","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and Pharmacological SGLT2 Inhibition in euglycemia. Am J Physiology-Renal Physiol. 2014;306(2):F188\u201393. https:\/\/doi.org\/10.1152\/ajprenal.00518.2013.","journal-title":"Am J Physiology-Renal Physiol"},{"issue":"15","key":"7593_CR2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Wheeler DC. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"22","key":"7593_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"8","key":"7593_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Sabatine MS. Effects of Dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317. https:\/\/doi.org\/10.1016\/S2213-8587(19)30180-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"7593_CR5","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Woodward M. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metabolism. 2019;21(5):1237\u201350. https:\/\/doi.org\/10.1111\/dom.13648.","journal-title":"Diabetes Obes Metabolism"},{"issue":"1","key":"7593_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2337\/cd22-as01","volume":"40","author":"American Diabetes Association","year":"2022","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142022 abridged for primary care providers. Clin Diabetes. 2022;40(1):10\u201338. https:\/\/doi.org\/10.2337\/cd22-as01.","journal-title":"Clin Diabetes"},{"issue":"3","key":"7593_CR7","doi-asserted-by":"publisher","first-page":"e0297378","DOI":"10.1371\/journal.pone.0297378","volume":"19","author":"SS Bay","year":"2024","unstructured":"Bay SS, Kamaruzaman L, Mohd R, Shah SA. Work disability and employment status among advanced chronic kidney disease patients. PLoS ONE. 2024;19(3):e0297378. https:\/\/doi.org\/10.1371\/journal.pone.0297378.","journal-title":"PLoS ONE"},{"key":"7593_CR8","unstructured":"CodeBlue. (2024, October 18). SGLT2 inhibitors for diabetes, SSB tax increase: Budget 2025. CodeBlue. https:\/\/codeblue.galencentre.org\/2024\/10\/sglt2-inhibitors-for-diabetes-ssb-tax-increase-budget-2025\/"},{"key":"7593_CR9","unstructured":"Wikipedia contributors. (2024, October 16). Demographics of Malaysia. Wikipedia. https:\/\/en.wikipedia.org\/wiki\/Demographics_of_Malaysia"},{"key":"7593_CR10","doi-asserted-by":"crossref","unstructured":"Abdul Kadir WNW et al. Real-world evidence for the use of SGLT2 inhibitors in patients with type 2 diabetes at a Malaysian tertiary care centre. J ASEAN Federation Endocr Soc. 2023; 38: 52. https:\/\/asean-endocrinejournal.org","DOI":"10.15605\/jafes.038.AFES.74"},{"issue":"3","key":"7593_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrneph.2017.181","volume":"14","author":"JJ Carrero","year":"2018","unstructured":"Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nat Rev Nephrol. 2018;14(3):151\u201364. https:\/\/doi.org\/10.1038\/nrneph.2017.181.","journal-title":"Nat Rev Nephrol"},{"key":"7593_CR12","doi-asserted-by":"publisher","unstructured":"Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., \u2026 EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 2015; 373(22), 2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","DOI":"10.1056\/NEJMoa1504720."},{"issue":"12","key":"7593_CR13","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/dom.13080","volume":"19","author":"Y Liu","year":"2017","unstructured":"Liu Y, Xie J, Zeng L. Effects of SGLT-2 inhibitors on kidney function and albuminuria in diabetic patients: A meta-analysis of randomized controlled trials. Diabetes Obes Metabolism. 2017;19(12):1690\u20138. https:\/\/doi.org\/10.1111\/dom.13080.","journal-title":"Diabetes Obes Metabolism"},{"issue":"4","key":"7593_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.kint.2018.12.037","volume":"95","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Xu H, Zhou M. Impact of SGLT-2 inhibitors on renal outcomes in patients with chronic kidney disease and diabetes. Kidney Int. 2019;95(4):993\u20131003. https:\/\/doi.org\/10.1016\/j.kint.2018.12.037.","journal-title":"Kidney Int"},{"key":"7593_CR15","doi-asserted-by":"publisher","unstructured":"Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan,D. M., \u2026 Mahaffey, K. W. (2019). Canagliflozin and kidney outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","DOI":"10.1056\/NEJMoa1811744."},{"issue":"3","key":"7593_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2024.04.002","volume":"14","author":"KDIGO","year":"2024","unstructured":"KDIGO. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2024;14(3):1\u2013140. https:\/\/doi.org\/10.1016\/j.kisu.2024.04.002.","journal-title":"Kidney Int Supplements"},{"key":"7593_CR17","doi-asserted-by":"publisher","unstructured":"Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus,M., \u2026 Zinman, B. Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine, 2016; 375(4), 323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920.","DOI":"10.1056\/NEJMoa1515920."},{"issue":"1","key":"7593_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2013;3(1):1\u2013150. https:\/\/doi.org\/10.1038\/kisup.2012.73.","journal-title":"Kidney Int Supplements"},{"issue":"3","key":"7593_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2021.05.001","volume":"11","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2021 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2021;11(3):1\u2013115. https:\/\/doi.org\/10.1016\/j.kisu.2021.05.001.","journal-title":"Kidney Int Supplements"},{"issue":"12","key":"7593_CR20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345. https:\/\/doi.org\/10.2215\/CJN.11491116.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"7593_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ajkd.2019.01.018","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120\u201331. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.018.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"7593_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/heartjnl-2018-313085","volume":"105","author":"CJ Bailey","year":"2019","unstructured":"Bailey CJ, Day C. Antidiabetic drugs and their impact on cardiovascular disease in patients with type 2 diabetes. Heart. 2019;105(9):600\u20136. https:\/\/doi.org\/10.1136\/heartjnl-2018-313085.","journal-title":"Heart"},{"key":"7593_CR23","unstructured":"Institute for Public Health. National health and morbidity survey 2019: Non-communicable diseases, healthcare demand and health literacy. Ministry Health Malaysia. 2020. https:\/\/www.iku.gov.my"},{"key":"7593_CR24","doi-asserted-by":"publisher","unstructured":"Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., \u2026CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 2017; 377(7), 644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","DOI":"10.1056\/NEJMoa1611925."},{"key":"7593_CR25","doi-asserted-by":"publisher","unstructured":"Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck,M., \u2026 Matthews, D. R. Management of hyperglycemia in type 2 diabetes, 2020:A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2020; 43(2), 487\u2013493. https:\/\/doi.org\/10.2337\/dci19-0066.","DOI":"10.2337\/dci19-0066."}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-025-07593-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07593-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:11:54Z","timestamp":1767888714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-025-07593-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7593"],"URL":"https:\/\/doi.org\/10.1186\/s13104-025-07593-6","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (MOH) (NMRR ID-24-03790-KHH). All procedures were performed in accordance with institutional and national research standards, the Declaration of Helsinki and its amendments, and the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) Guidelines. The requirement for informed consent was waived due to the retrospective design of the study and the use of anonymised data in line with institutional and national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}